文献速递眼底病与葡萄膜炎

VEGF-Grab 的临床前疗效与安全性及其与阿柏西普的比较

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

本研究在体外细胞实验及小鼠氧诱导视网膜病变(OIR)、大鼠激光诱导脉络膜新生血管(CNV)模型中评估新型抗 VEGF 药物 VEGF-Grab 的疗效与视网膜毒性,并与阿柏西普比较。结果显示 VEGF-Grab 体外抗 VEGF 活性优于阿柏西普,体内抗血管生成疗效及视网膜安全性与之相当,可能成为新生血管性视网膜疾病的候选药物。

要点

  • VEGF-Grab 体外抑制 VEGF 诱导的细胞增殖与迁移优于阿柏西普,但管腔形成抑制与之相当。
  • 在 OIR 与激光诱导 CNV 模型中,VEGF-Grab 体内抗血管生成疗效与阿柏西普相当。
  • 小鼠玻璃体腔注射后 7 天和 30 天,两种药物均未见明显视网膜毒性征象。

核心结论

  • 与阿柏西普相比,VEGF-Grab 体内抗血管生成疗效相当,体外抗 VEGF 活性更优,两者视网膜安全性特征相当。
  • 鉴于 VEGF-Grab 对 VEGF 和胎盘生长因子(PlGF)的亲和力高于阿柏西普,其可能成为新生血管性视网膜疾病的候选药物及阿柏西普的替代选择。

研究设计与样本

  • 体外采用 VEGF 诱导的细胞增殖、迁移和管腔形成实验检测 VEGF-Grab 的抗 VEGF 效力。
  • 体内采用小鼠氧诱导视网膜病变(OIR)模型和大鼠激光诱导脉络膜新生血管(CNV)模型评估玻璃体腔注射 VEGF-Grab 或阿柏西普的抗血管生成疗效。
  • 采用光镜和电镜评估小鼠眼内注射两种药物后的视网膜毒性。

主要发现

  • VEGF-Grab 对 VEGF 诱导的细胞增殖和迁移的抑制作用强于阿柏西普,但对管腔形成的抑制作用与阿柏西普相当。
  • 在 OIR 模型中,VEGF-Grab 对 retinal neovascularization 的抑制与阿柏西普相当。
  • 在激光诱导 CNV 模型中,VEGF-Grab 抑制 CNV 的疗效与阿柏西普相似。
  • 组织学和透射电镜显示,玻璃体腔注射 VEGF-Grab 或阿柏西普后 7 天和 30 天小鼠视网膜均无明显毒性征象。

临床怎么用

  • 临床前数据提示 VEGF-Grab 在体内抗血管生成疗效和视网膜安全性上不劣于阿柏西普,可支持其进一步开展临床研究。
  • 其体外抗 VEGF 活性更优及对 PlGF 更高亲和力,可能为新生血管性视网膜疾病提供阿柏西普之外的候选选择。

局限性

  • 研究为临床前体外及动物模型实验,结果尚不能直接推及人体疗效与安全性。
  • 原文未报告临床研究数据及长期安全性随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: VEGF-Grab is a novel anti-vascular endothelial growth factor (VEGF) candidate drug with higher affinity to both VEGF and placental growth factor (PlGF) compared to aflibercept. We investigated the preclinical efficacy of VEGF-Grab for ophthalmic therapy and compared it to that of aflibercept. METHODS: The in vitro anti-VEGF efficacy of VEGF-Grab was determined using VEGF-induced cell proliferation/migration and tube formation assays. The in vivo antiangiogenic efficacy of intravitreal injection of either VEGF-Grab or aflibercept was evaluated using murine models of ocular angiogenesis: mouse oxygen-induced retinopathy (OIR) and rat laser-induced choroidal neovascularization (CNV). The in vivo retinal toxicity in the mouse eye resulting from the injection of either drug was evaluated with light and electron microscopy. RESULTS: VEGF-Grab showed greater inhibition of VEGF-induced cell proliferation/migration than aflibercept, but it showed comparable inhibition of tube formation in vitro. In the in vivo OIR model, VEGF-Grab showed a comparable suppression of retinal neovascularization compared to aflibercept. Additionally, VEGF-Grab showed an efficacy similar to that of aflibercept in terms of CNV inhibition in the laser-induced CNV model. Histology and transmission electron microscopy showed no significant signs of toxicity in the mouse retina at 7 and 30 days following the intravitreal injection of VEGF-Grab or aflibercept. CONCLUSIONS: Compared to aflibercept, VEGF-Grab presented comparable in vivo antiangiogenic efficacy and superior in vitro anti-VEGF activity. The retinal safety profiles were comparable for the two drugs. Considering its known higher binding affinity to VEGF and PlGF compared to aflibercept, VEGF-Grab could be a potential candidate drug for neovascular retinal diseases and an alternative to aflibercept.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hong HK, Park YJ, Kim DK, et al. Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept. Invest Ophthalmol Vis Sci. 2020. PMID: 33196778. doi:10.1167/iovs.61.13.22

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。